Pay in 4 interest-free payments of $7.31 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
This approach is commonly used in medical practice, particularly for patients who require stronger metabolic support beyond a single medication
Request a certificate of analysis (CoA) from the manufacturer if the oxidation state is unclear
Relative contraindications requiring caution include active or suspected cancer (GHK-Cu promotes angiogenesis with concern about theoretically feeding tumors, though conflicting data shows documented anti-cancer gene expression effects requiring medical supervision), severe organ dysfunction (kidney or liver failure may slow peptide clearance), hemochromatosis or copper overload conditions, autoimmune disorders, and patients on immunosuppressants or blood thinners
Comparative Trials Head-to-head data suggest tirzepatide (Zepbound) achieved ~20.2% mean weight loss at 72 weeks versus ~13.7% with semaglutide (Wegovy)
